NLGN3 acts as a mitogen by recruiting PI3K‐mTOR oncogenic pathway to induce glioma cells proliferation.[41] In 2019, two studies showing the electrical and synaptic integration of glioma cells in neuronal circuits were published.[42, 43] Both studies demonstrated the existence of spontaneous, excitatory postsynaptic potentials in tumor cells mediated by α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, which could bring to the fore new therapeutic strategies for high‐grade gliomas. Here, NLGN3 is linked to central nervous system cancer.